Hikma Pharmaceuticals Plc Notice to Bondholders (9536C)

TIDMHIK

RNS Number : 9536C

Hikma Pharmaceuticals Plc

22 October 2020

London, October 22, 2020

Hikma Finance USA LLC (the "Issuer")

Notice to the holders of the US$500,000,000 3.250 per cent. Guaranteed Notes due 2025 (the "Notes")

The Issuer refers to the terms and conditions of the Notes (the "Conditions") set out in the offering circular dated 7 July 2020. Capitalised terms used in this notice and not defined herein shall have the meaning set out in the Conditions.

Fitch Ratings has today announced that it has assigned Hikma Pharmaceuticals Plc (Hikma, Company) a 'BBB-' first-time Long-Term Issuer Default Rating (outlook: Stable). Hikma's existing rating of BBB- (outlook: Stable) from S&P remains unchanged, and accordingly the Company has achieved investment grade status from two rating agencies in accordance with the Conditions.

The Company's obligations under Condition 5.2 (Limitation on Indebtedness) and Condition 5.4 (Guarantor Group) of the Terms and Conditions of the Notes have therefore been suspended with effect from 22 October 2020, and shall remain suspended for so long as the Company retains its investment grade status, all in accordance with the Conditions.

- ENDS -

Enquiries

Hikma Pharmaceuticals PLC

 
Susan Ringdal                                [phone]/ +44 7776 
 EVP, Strategic Planning and Global Affairs   477050 
                                              [e-mail] 
 

About Hikma

Hikma Pharmaceuticals PLC (LSE: HIK) (NASDAQ Dubai: HIK) (OTC: HKMPY) (LEI:549300BNS685UXH4JI75) (rated BBB-/stable S&P, BBB-/stable Fitch and Ba1/stable Moody's)

Hikma helps put better health within reach every day for millions of people in more than 50 countries around the world. For more than 40 years, we've been creating high-quality medicines and making them accessible to the people who need them. Headquartered in the UK, we are a global company with a local presence across the United States (US), the Middle East and North Africa (MENA) and Europe, and we use our unique insight and expertise to transform cutting-edge science into innovative solutions that transform people's lives. We're committed to our customers, and the people they care for, and by thinking creatively and acting practically, we provide them with a broad range of branded and non-branded generic medicines. Together, our 8,600 colleagues are helping to shape a healthier world that enriches all our communities. We are a leading licensing partner, and through our venture capital arm, are helping bring innovative health technologies to people around the world. For more information, please visit: www.hikma.com

(c)2020 Hikma Pharmaceuticals PLC. All rights reserved.

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact [e-mail] or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.

END

DOCUUAURRUURUAA

(END) Dow Jones Newswires

October 22, 2020 08:16 ET (12:16 GMT)